{
  "subset": "contraindication",
  "disease": "Familial pulmonary fibrosis",
  "relation": "contraindication",
  "gold_drugs": [
    "bardoxolone methyl",
    "deoxycytidine",
    "deoxythymidine",
    "peg ifn-α-2b",
    "saracatinab"
  ],
  "seeds_initial": [
    "Saracatinib",
    "Ambrisentan",
    "Nintedanib",
    "Pirfenidone",
    "Amiodarone",
    "Bleomycin",
    "Methotrexate",
    "Cyclophosphamide",
    "Nitrofurantoin",
    "Procarbazine",
    "Hydrochlorothiazide",
    "Busulfan"
  ],
  "seed_history": [
    [
      "Saracatinib",
      "Ambrisentan",
      "Nintedanib",
      "Pirfenidone",
      "Amiodarone",
      "Bleomycin",
      "Methotrexate",
      "Cyclophosphamide",
      "Nitrofurantoin",
      "Procarbazine",
      "Hydrochlorothiazide",
      "Busulfan"
    ]
  ],
  "final_report": {
    "final_recommendations": [
      {
        "hypothesis_id": "H1",
        "candidate": {
          "id": "drug_saracatinib",
          "name": "Saracatinib"
        },
        "score": 0.57,
        "graph_snapshot_ref": "GE_H1_round4",
        "key_assumptions": [
          "Saracatinib contraindicated due to adverse reaction risks specific to pulmonary fibrosis."
        ],
        "caveats": [
          "Need further validation on specific impacts on familial pulmonary fibrosis."
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H2",
        "candidate": {
          "id": "drug_ambrisentan",
          "name": "Ambrisentan"
        },
        "score": 0.57,
        "graph_snapshot_ref": "GE_H2_round4",
        "key_assumptions": [
          "Ambrisentan contraindicated due to association with lung diseases."
        ],
        "caveats": [
          "Need further validation on specific impacts on familial pulmonary fibrosis."
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H3",
        "candidate": {
          "id": "drug_nintedanib",
          "name": "Nintedanib"
        },
        "score": 0.57,
        "graph_snapshot_ref": "GE_H3_round4",
        "key_assumptions": [
          "Nintedanib contraindicated as it is used to treat specific fibrosis."
        ],
        "caveats": [
          "Need further validation on specific impacts on familial pulmonary fibrosis."
        ],
        "confidence": "medium"
      },
      {
        "hypothesis_id": "H4",
        "candidate": {
          "id": "drug_pirfenidone",
          "name": "Pirfenidone"
        },
        "score": 0.57,
        "graph_snapshot_ref": "GE_H4_round4",
        "key_assumptions": [
          "Pirfenidone contraindicated due to clinical observations of side effects."
        ],
        "caveats": [
          "Need further validation on specific impacts on familial pulmonary fibrosis."
        ],
        "confidence": "medium"
      }
    ],
    "audit_report": {
      "decisive_graph_motifs": [
        {
          "pattern": "Drug→Familial pulmonary fibrosis (contraindication)",
          "reason": "Established contraindications and significant adverse reaction risks."
        }
      ],
      "remaining_gaps": [
        "Validation of specific drug impacts on familial pulmonary fibrosis."
      ]
    },
    "seed_retrospective": {
      "batches": [
        {
          "round": 1,
          "seeds": [],
          "impact_summary": "No prior seeds have been generated."
        }
      ],
      "lessons": []
    },
    "prompt_patches": [],
    "heuristics": []
  },
  "experience_used": true,
  "explorer_prompt": "List drugs that are contraindicated or could worsen the rare disease 'Familial pulmonary fibrosis'. Return only names.\n\n# Heuristics:\n- When 针对纤维化相关表型: then 关注临床安全性与疗效；需严谨数据支持新疗法预期效益。"
}